Status: Recruiting
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity to determine the preliminary recommended dose for expansion (RDE) of NKT3964 in adults with advanced or metastatic solid tumors. The goal of the Expansion phase of the study is to evaluate the preliminary anti-tumor activity of NKT3964 at the RDE based on objective response rate (ORR) and determine the preliminary recommended Phase 2 dose (RP2D).
Participants needed: 150
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: NiKang Therapeutics, Inc.Updated: Apr 21, 2026Locations: 19
Eligibility criteria
Ovarian cancer [+10]
Locally advanced solid tumor that is a candidate for curative treatment through... [+13]